Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company operates in a highly competitive and fragmented segment with many players around. The sudden boost in its bottom line for 9M FY23 raises eyebrows and concern over sustainability going forward. Based on such super earnings, the issue appears greedily priced, while based on its track records, it appears exorbitantly priced. There is no harm in skipping this pricey issue. Read detail review...
Vilin Bio Med Limited peer comparison with similar listed entities. () (As on March 31, 2022)
Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
---|---|---|---|---|
EPS Basic | ||||
Vilin Bio Med Limited | 0.04 | 8.96 | 294.82 | 0.45 |
JFL Life Sciences Limited | 3.77 | 42.66 | 10.82 | 25.20 |
Vaishali Pharma Limited | 3.82 | 24.99 | 33.77 | 15.27 |
Anuh Pharma Limited | 6.10 | 6.10 | 14.70 | 14.30 |
Notes:
Vilin Bio Med IPO Reviews, analysis and views by popular members. Read Vilin Bio Med Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Note: